Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial
Brian Jarman, Brian Hurwitz, Adrian Cook, Madhavi Bajekal, Alison Lee, Brian Jarman, Brian Hurwitz, Adrian Cook, Madhavi Bajekal, Alison Lee
Abstract
Objective: To determine the effects of community based nurses specialising in Parkinson's disease on health outcomes and healthcare costs.
Design: Two year randomised controlled trial.
Setting: 438 general practices in nine randomly selected health authority areas of England.
Participants: 1859 patients with Parkinson's disease identified by the participating general practices.
Main outcome measures: Survival, stand-up test, dot in square test, bone fracture, global health question, PDQ-39, Euroqol, and healthcare costs.
Results: After two years 315 (17.3%) patients had died, although mortality did not differ between those who were attended by nurse specialists and those receiving standard care from their general practitioner (hazard ratio for nurse group v control group 0.91, 95% confidence interval 0.73 to 1.13). No significant differences were found between the two groups for the stand-up test (odds ratio 1.15, 0.93 to 1.42) and dot in square score (difference -0.7, -3.25 to 1.84). Scores on the global health question were significantly better in patients attended by nurse specialists than in controls (difference -0.23, -0.4 to -0.06), but no difference was observed in the results of the PDQ-39 or Euroqol questionnaires. Direct costs for patient health care increased by an average of 2658 pounds sterling during the study, although not differentially between groups: the average increase was 266 pounds sterling lower among patients attended by a nurse specialist (-981 pounds sterling to 449 pounds sterling ).
Conclusions: Nurse specialists in Parkinson's disease had little effect on the clinical condition of patients, but they did improve their patients' sense of wellbeing, with no increase in patients' healthcare costs.
Figures
References
- Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. BMJ. 1986;292:534–536.
- Ben-Shlomo Y, Sieradzan K. Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Brit J Gen Pract. 1995;45:261–268.
- Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ. 2000;321:21–22.
- Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993;329:1021–1027.
- Münchau A, Bhatia KP. Pharmacological treatment of Parkinson's disease. Postgrad Med J. 2000;76:602–610.
- Mutch WJ, Strudwick A, Roy SK, Downie AW. Parkinson's disease: disability, review, and management. BMJ. 1986;293:675–677.
- College of Health. The needs of people with Parkinson's disease. London: College of Health; 1994.
- Ridsdale L. Community care for patients with idiopathic Parkinson's disease. Brit J Gen Pract. 1995;394:226–227.
- Parkinson's Disease Society. Parkinson's disease and the nurse. London: Parkinson's Disease Society; 1999.
- MacMahon DG, Thomas S. Practical approach to quality of life in Parkinson's disease: the nurse's role. J Neurol. 1998;245(suppl 1):19–22S.
- Wilson-Barnett J, Beech S. Evaluating the clinical nurse specialist. A review. Int J Nurs Stud. 1994;31:561–571.
- Jahanshahi M, Brown C, Whitehouse C, Quinn N, Marsden CD. Contact with a nurse practitioner: a short-term evaluation study in Parkinson's disease and dystonia. Behav Neurol. 1994;7:189–196.
- Jarman B. Identification of underprivileged areas. BMJ. 1983;312:1705–1709.
- Jarman B. Underprivileged areas: validation and distribution of scores. BMJ. 1984;289:1587–1592.
- School of Nursing and Midwifery. Knowledge based practice for people with Parkinson's disease and their carers. Sheffield: School of Nursing and Midwifery, Northern General Hospital; 2000.
- Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson's disease. Qual Life Res. 1995;4:241–248.
- Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self-reported functioning and well-being in patients with Parkinson's disease: a comparison of the short-form health survey (SF-36) and the Parkinson's disease questionnaire (PDQ 39) Age Ageing. 1995;24:505–509.
- Jenkinson C, Fitzpatrick R, Peto V. The Parkinson's disease questionnaire. Oxford: Health Services Research Unit, Department of Public Health, University of Oxford; 1998.
- Williams A. The measurement and validation of health: a chronicle. York: Centre for Health Economics, University of York; 1995. . (Discussion paper 136.)
- Gerstenbrand F, Grunberger J, Schubert H. Quantitative testmethoden zur objecktivierung des effekts einer L-Dopalangzeittherapie beim Parkinson-syndrom. Nervenarzt. 1973;44:428–433.
- Wade DT. Measurement in neurological rehabilitation. Oxford: Oxford University Press; 1994.
- Netten A, Denett J. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit; 1996.
- The monthly index of medical specialities 1996 net ingredient costs. London: Haymarket Medical; 1996.
- Hurwitz B, Bajekal M, Jarman B. Evaluating community-based Parkinson's disease nurse specialists—rationale, methodology and representativeness of patient sample in a large randomised controlled trial. In: Stern G, ed. Parkinson's disease. Advances in neurology. Volume 80. Philadelphia: Lippincott, Williams, and Wilkins, 1999:431-9.
- Thompson SG, Barber A. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197–1200.
- MacMahon DG, Findley L, Holmes J, Pugner K. The true economic impact of Parkinson's disease: a research survey in the UK. Movement Disorders. 2000;15(suppl 3):178. . (Poster No 861.)
- Reynolds H, Wilson-Barnett, Richardson G. Evaluation of the role of the Parkinson's disease nurse specialist. Nurs Stud. 2000;37:337–349.
- Lees AJ. On behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ. 1995;311:1602–1607.
- Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing. 2001;30:299–302.
- Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994;57:672–681.
Source: PubMed